197 related articles for article (PubMed ID: 23275642)
1. Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan.
Ioka T; Katayama K; Tanaka S; Takakura R; Ashida R; Kobayashi N; Taniai H
Jpn J Clin Oncol; 2013 Feb; 43(2):139-45. PubMed ID: 23275642
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan.
Okubo S; Nishiuma S; Kobayashi N; Taketsuna M; Taniai H
Jpn J Clin Oncol; 2012 Nov; 42(11):1043-53. PubMed ID: 23042772
[TBL] [Abstract][Full Text] [Related]
3. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
6. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
[TBL] [Abstract][Full Text] [Related]
8. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.
Furuse J; Gemma A; Ichikawa W; Okusaka T; Seki A; Ishii T
Jpn J Clin Oncol; 2017 Sep; 47(9):832-839. PubMed ID: 28541474
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
10. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
Sakamoto H; Kitano M; Suetomi Y; Takeyama Y; Ohyanagi H; Nakai T; Yasuda C; Kudo M
J Gastroenterol; 2006 Jan; 41(1):70-6. PubMed ID: 16501860
[TBL] [Abstract][Full Text] [Related]
11. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.
Eckel F; Schmelz R; Erdmann J; Mayr M; Lersch C
Cancer Invest; 2003; 21(5):690-4. PubMed ID: 14628426
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
14. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.
Oberstein PE; Hershman DL; Khanna LG; Chabot JA; Insel BJ; Neugut AI
Cancer Invest; 2013 Jun; 31(5):316-22. PubMed ID: 23614655
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Viaud J; Brac C; Artru P; Le Pabic E; Leconte B; Bodère A; Pracht M; Le Sourd S; Edeline J; Lièvre A
Dig Liver Dis; 2017 Jun; 49(6):692-696. PubMed ID: 28256401
[TBL] [Abstract][Full Text] [Related]
16. [Clinical problems in gemcitabine treatment for unresectable pancreatic cancer in the elderly--a multicentric retrospective study of 53 cases].
Takeuchi N; Maejima S; Hasebe O; Matsuda Y; Hanazaki K; Kajikawa S; Mukawa K; Hosokawa K; Hayashi K; Hisa T; Furut K; Tajiri K; Fujimori Y; Kaneko G; Ochi Y; Shikama N; Kawa S; Miyagawa S; Miwa S; Kiyosawa K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1987-91. PubMed ID: 15570926
[TBL] [Abstract][Full Text] [Related]
17. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Saif MW
JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
[TBL] [Abstract][Full Text] [Related]
19. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Brand R; Capadano M; Tempero M
Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
